Fluoroquinolones for treating tuberculosis (presumed drug-sensitive)

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  Ziganshina, Lilia E ^a   Titarenko, Albina F ^a   Davies, Geraint R ^b  

^a KAZAN FEDERAL UNIVERSITY   (Russian Federation)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; CIPROFLOXACIN; LEVOFLOXACIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; EVIDENCE BASED MEDICINE; HUMAN; LUNG TUBERCULOSIS; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; RISK FACTOR; SPUTUM CULTURE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS; DRUG SUBSTITUTION; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; CIPROFLOXACIN; DRUG SUBSTITUTION; FLUOROQUINOLONES; HUMANS; LEVOFLOXACIN; OFLOXACIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84891690000     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD004795.pub4     Document Type: Review

References (119)

1. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, et al.Moxifloxacin versus ethambutol in the first two months of treatment for pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine 2006;174(3):331-8.
2. Conde MB, Efron A, Loredo C, De Souza GR, Graca NP, Cezar MC, et al.Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009;373(9670):1183-9.
3. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, et al.Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine 2009;180(3):273-80.
4. El-Sadr WM, Perlman DC, Matts JP, Nelson ET, Cohn DL, Salomon N, et al.Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clinical Infectious Diseases 1998;26(5):1148-58.
5. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, et al.A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. International Journal of Tuberculosis and Lung Disease 2008;12(2):128-38.
6. Abdullah A, Abu-Hussein AH, Al-Akshar M, Abdel R, Ads CH, El Taieb S. Ofloxacin in the treatment of primary drug resistant pulmonary tuberculosis (PDR-TB). European Respiratory Journal 1997;10(Suppl):25214.
7. Abdullah A, Abu-Hussein AH, Al-Akshar M, Ads CH, El-Taieb S. Ofloxacin dosage in the treatment of multidrug resistant pulmonary tuberculosis (MDR-TB). European Respiratory Journal 1998;12(Suppl):28367.
8. Agarwal SK. Treatment of resistant tuberculosis in Indian patients of Eastern Uttar Pradesh having isolates resistant to isoniazid, rifampicin and quinolones. Respirology 2007;12(4):A114.
9. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs LM, Winkler H, et al.A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307(5707):223-7.
10. Anonymous. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Hong Kong Chest Service/British Medical Research Council. Tubercle and Lung Disease 1997;73(1):59-67.
11. Barmina NA, Burukhina LV, Shurygin AA, Archakova LI. Roncoleukin in enhancing the efficiency of complex therapy for infiltrative pulmonary tuberculosis in adolescents. Problemy Tuberkuleza i Boleznei Legkikh 2009;5:27-31.
12. Bartacek A, Schutt D, Panosch B, Borek M, Rimstar 4-FDC Study Group. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. International Journal of Tuberculosis and Lung Disease 2009;13(6):760-6.
13. Carroll MW, Choi H, Min S, Hwang S, Park H, Song T, et al.Rhabdomyolysis in a patient treated with linezolid for extensively drug-resistant (XDR) tuberculosis. Clinical Infectious Diseases 2012;54(11):1624-7.
14. Chambers HF, Kocagoz T, Sipit T, Turner J, Hopewell PC. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clinical Infectious Diseases 1998;26(4):874-7.
15. Chang KC, Leung CC, Yew WW, Lau TY, Tam CM. Hepatotoxicity of pyrazinamide: Cohort and case-control analyses. American Journal of Respiratory and Critical Care Medicine 2008;177(12):1391-6.
16. Chang KC, Leung CC, Yew WW, Lau TY, Leung WM, Tam CM, et al. Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis?. European Respiratory Journal 2009;35(3):606-13.
17. Chen QL, Chen L, Yin JJ. A study on the clinical efficacy of a combination regimen with levofloxacin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Diseases] 2003;26(8):454-7.
18. Chigutsa E, Meredith S, Wiesner L, Padayatchi N, Harding J, Moodley P, et al.Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients With multi-drug resistant tuberculosis. Antimicrobial Agents and Chemotherapy 2012;56(7):3857-63.
19. Chukanov VI, Komissarova OG, Maishin VI, Abdullaev RI, Kononets AS. Efficiency of a new standard chemotherapy regimen in the treatment of patients with recurrent pulmonary tuberculosis. Problemy Tuberculeza i Boleznej Legkikh 2006, issue 8:9-13.
20. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al.The diarylquinoline TMC207 for multidrug-resistant tuberculosis. New England Journal of Medicine 2009;360(23):2397-405.
21. Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, et al.Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability and effect on emergence of drug resistance. Antimicrobial Agents and Chemotherapy 2012;56(6):3271-6.
22. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, et al.14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012;380(9846):986-93.
23. Estebanez Zarranz MJ, Martinez-Sagarra JM, Alberte A, Amon Sesmero J, Rodriguez Toves A. Treatment of urogenital tuberculosis with ofloxacin. Preliminary study. Actas Urologicas Espanolas 1992;16(1):64-8.
24. Fouad M, Gallagher JC. Moxifloxacin as an alternative or additive therapy for treatment of pulmonary tuberculosis. Annals of Pharmacotherapy 2011;45(11):1439-44.
25. Gosling RD, Uiso LO, Sam NE, Bongard E, Kanduma EG, Nyindo M, et al.The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine 2003;168(11):1342-5.
26. Grishin VK, Polunina TE. Lomefloxacin in phthisiatric practice. Antibiotiki i Khimioterapiia 1998;43(10):17-8.
27. Heemskerk D, Day J, Chau TT, Dung NH, Yen NT, Bang ND, et al.Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial. Trials 2011;12(25):1-11.
28. Ho CC, Chen YC, Liao WY, Tsai TH, YU CJ, Yang PC, et al.Safety of fluoroquinolone in the treatment of tuberculosis patients with hepatotoxicity induced by first-line antituberculosis regimens [Abstract]. Respirology 2007;12((Suppl 4)):A240.
29. Huang CS, Wu CC. Observation of the clinical efficacy of sparfloxacin in the treatment of multiple drug resistance pneumonial tuberculosis. Chinese Journal of Antibiotics 2000;25(4):302-3.
30. Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith AP. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax 2008;63(7):627-34.
31. Ji YM, Dong LH, Wang Q, Yu WQ. Short-term observating of curative effects in treatment of multiple-drug resistance pulmonary tuberculosis with sparfloxacin and ofloxacin. Journal of Postgraduates of Medicines 2001;24(7):32-3.
32. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, et al.Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. International Journal of Tuberculosis and Lung Disease 2006;10(6):605-12.
33. Kang WL, Xie YG, Tan WG, Chu NH, Li L, You YH, et al.Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis. Zhonghua Liu Xing Bing Xue Za Zhi 2009;30(2):179-83.
34. Kawahara S, Eirei J. Evaluation of new antitubercular agents- new quinolone agents. Kekkaku 1992;67(10):679-82.
35. Kennedy N, Fox R, Uiso L, Ngowi FI, Gillespie SH. Safety profile of ciprofloxacin during long-term therapy for pulmonary tuberculosis. Journal of Antimicrobial Chemotherapy 1993;32(6):897-902.
36. Kennedy N, Berger L, Curram J, Fox R, Gutmann J, Kisyombe GM, et al.Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clinical Infectious Diseases 1996;22(5):827-33.
37. Kennedy N, Fox R, Kisyombe GM, Saruni AO, Uiso LO, Ramsay AR, et al.Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. American Review of Respiratory Disease 1993;148(6 Pt 1):1547-51.
38. Kohno S, Koga H, Kaku M, Maesaki S, Hara K. Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. Chest 1992;102(6):1815-8.
39. Kumar AK, Gurumurthy P. Disposition of uric acid upon administration of ofloxacin alone and in combination with other anti-tuberculosis drugs. Indian Journal of Experimental Biology 2004;42(3):323-5.
40. Lee J, Lee CH, Kim DK, Yoon HI, Kim JY, Lee SM, et al.Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes. Korean Journal of Internal Medicine 2011;26(2):153-9.
41. Li L, Zheng SH, Chu NH, Xie YG, Yang YZ, Li Q, et al.Effects of two treatment regimens for drug-resistant tuberculosis in tuberculosis control project areas: a comparative study. Zhonghua Yi Xue Za Zhi 2008;88(48):3387-91.
42. Lu Y, Zhu L, Duan L. Antituberculosis effect of levofloxacin. Zhonghua Jie He He Hu Xi Za Zhi 2000;23(1):50-4.
43. Marra F, Marra CA, Moadebi S, Shi P, Elwood RK, Stark G, et al.Levofloxacin treatment of active tuberculosis and the risk of adverse events. Chest 2005;128(3):1406-13.
44. Merle CS, Sismanidis C, Sow OB, Gninafon M, Horton J, Lapujade O, et al.A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project. Trials 2012; Vol. 13, issue 61:1-10. [DOI: 10.1186/1745-6215-13-61]
45. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007;67(14):2077-99.
46. Mohanty KC, Dhamgaye TM. Controlled trial of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis. Chest 1993;104(4):1194-8.
47. Moulding T. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease 2008;12(9):1102.
48. Nakamura M, Hasegawa N, Miyao N, Nakajima T, Terashima T, Sakamaki F, et al.Comparison of five day short-course therapies for secondary infection in patients with chronic respiratory disease using gatifloxacin and levofloxacin. Japanese Journal of Chemotherapy 2007;55(6):451-62.
49. Nosova EIu, Galkina KIu, Antonova OV, Garmash IuIu, Skotnikova OI, Moroz AM. Use of molecular-biological microchip TB-BIOCHIP-2 for detecting of Mycobacterium tuberculosis with multidrug resistance to fluoroquinolones in patients with new detected and chronic tuberculosis. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk 2008;3:16-9.
50. O'Brien RJ, Nunn PP. Ciprofloxacin is not a component of first-line TB. Chest 1994;106(4):1312.
51. Peloquin CA, Hadad DJ, Molino LP, Palaci M, Boom WH, Dietze R, et al.Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrobial Agents and Chemotherapy 2008;52(3):852-7.
52. Pletz MW, De Roux A, Roth A, Neumann KH, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrobial Agents and Chemotherapy 2004;48(3):780-2.
53. Ruslami R, Ganiem AR, Dian S, Apriani L, Achmad TH, van der Ven AJ, et al.Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infectious Diseases 2013;13(1):27-35.
54. Rustomjee R, Diacon AH, Allen J, Venter A, Reddy C, Patientia RF, et al.Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrobial Agents and Chemotherapy 2008;52(8):2831-5.
55. Saigal S, Agarwal SR, Nandeesh HP, Sarin SK. Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report. Journal of Gastroenterology and Hepatology 2001;16(9):1028-32.
56. Sirgel FA, Botha FJ, Parkin DP, Van de Wal BW, Schall R, Donald PR, et al.The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine 1997;156(3 Pt 1):901-5.
57. Sirgel FA, Donald PR, Odhiambo J, Githui W, Umapathy KC, Paramasivan CN, et al.A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. Journal of Antimicrobial Chemotherapy 2000;45(6):859-70.
58. Sokolova GB, Kunichan AD, Koriakin VA, Lazareva IaV. Lomefloxacin in complex treatment of acute progressive form of pulmonary tuberculosis. Antibiotiki i Khimioterapiia 1998;43(10):10-2.
59. Sun W, Wenyi C, Cunzhi L, Yanhong Y, Yuzhen X, Zhaosheng S. A randomized controlled study of sparfloxacin and ofloxacin in the treatment of multiple drug resistant pulmonary tuberculosis. Chinese Journal of Antibiotics 2000;25(1):52-4.
60. Suo J, Yu MC, Lee CN, Chiang CY, Lin TP. Treatment of multidrug-resistant tuberculosis in Taiwan. Chemotherapy 1996;42(Suppl 3):20-3.
61. Thwaites GE, Bhavnani SM, Chau TT, Hammel JP, Torok ME, Van Wart SA, et al.Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrobial Agents and Chemotherapy 2011;55(7):3244-53.
62. Tuberculosis Research Centre (Indian Council of Medical Research), Chennei. Shortening short course chemotherapy: a randomized clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian Journal of Tuberculosis 2002;49(1):27-38.
63. Valerio G, Bracciale P, Manisco V, Quitadamo M, Legari G, Bellanova S. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. Journal of Chemotherapy 2003;15(1):66-70.
64. Venter WDF, Panz VR, Feldman Ch, Joffe BI. Adrenocortical function in hospitalised patients with active pulmonary tuberculosis receiving a rifampicin-based regimen - a pilot study. South African Medical Journal 2006;96(1):62-6.
65. Wang JY, Hsueh PR, Jan IS, Lee LN, Liaw YS, Yang PC, et al.Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006;61(10):903-8.
66. Wolbers M, Heemskerk D, Chau TT, Yen NT, Caws M, Farrar J, et al.Sample size requirements for separating out the effects of combination treatments: randomised controlled trials of combination therapy vs. standard treatment compared to factorial designs for patients with tuberculous meningitis. Trials 2011;12(26):1-7.
67. Yoon YS, Lee HJ, Yoon HI, Yoo CG, Kim YW, Han SK, et al.Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. International Journal of Tuberculosis and Lung Disease 2005;9(11):1215-9.
68. Yoon HE, Jeon YJ, Chung HW, Shin SJ, Hwang HS, Lee SJ, et al.Safety and efficacy of a quinolone-based regimen for treatment of tuberculosis in renal transplant recipients. Transplantation Proceedings 2012;44(3):730-3.
69. Zhang Y, Qian H, Chen M. Bronchofiberscope and catheter intervention in treatment of multi-drug resistant pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi 1997;20(6):354-7.
70. Zhang X, Li M, Hu CM, Yu J, Lin FS, Mao KJ, et al.Clinic assessment of rifabutin in the treatment of multidrug-resistant pulmonary tuberculosis. Chinese Journal of Antibiotics 2006;31(4):223-4, 242.
71. Zhao RZ, Wang QM, Zhang PC, Zhang HM. Therapeutic effects of levofloxacin-containing regimen in patients with retreated pulmonary tuberculosis. Chinese Journal of Antibiotics 2003;28(8):497-9.
72. Zheng XM, Li SM, Xing BC. Short-term effect of treatment protocol utilizing levofloxacin, pasiniazide and M. vaccae on multi-drug resistant pulmonary tuberculosis. Di Yi Jun Yi Da Xue Xue Bao [Academic Journal of the First Medical College of PLA] 2004;24(5):574-5.
73. Zhu LZ, Fu Y, Chu NH, Ye ZZ, Xiao HP, Wang W, et al.A controlled clinical trial of long course chemotherapy regimens containing rifabutin in the treatment of multi-drug resistant pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi 2006;29(8):520-3.
74. Zhu H, Lei X, Zhang F, Zhang ZJ, Lu J, Li H, et al.Effectiveness and safety of levofloxacin for multidrug resistant pulmonary tuberculosis: A systematic review. Chinese Journal of Evidence-Based Medicine 2012;12(2):201-8.
75. Zvada SP, Denti P, Geldenhuys H, Meredith S, van As D, Hatherill M, et al.Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine. Antimicrobial Agents and Chemotherapy 2012;56(8):4471-3.
76. ICMR. Thrice weekly 4-months moxifloxacin or gatifloxacin regimens for pulmonary TB [A study of the efficacy and tolerability of moxifloxacin and gatifloxacin containing regiments in the treatment of patients with sputum-positive pulmonary tuberculosis]. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=5124 (accessed in March 2013).
77. ISRCTN44153044. An international multicentre controlled clinical trial to evaluate high dose RIFApentine and a QUINolone in the treatment of pulmonary tuberculosis. www.controlled-trials.com/ISRCTN44153044/ISRCTN44153044 (accessed 27 July 2007).
78. NCT00216385. A controlled trial of a 4-month quinolone-containing regimen for the treatment of pulmonary tuberculosis. clinicaltrials-nccs.nlm.nih.gov/ct2/show/NCT00216385 (accessed 23 July 2007).
79. NCT00396084. Randomized, open label, multiple dose Phase I study of the early bactericidal activity of linezolid, gatifloxacin, levofloxacin, and moxifloxacin in HIV-non-infected adults with Initial episodes of sputum smear-positive pulmonary tuberculosis (DMID 01-553). clinicaltrials.gov/ct/show/NCT00396084?order=11 (accessed 27 July 2007).
80. NCT00728507. A phase II randomized, open-label trial of a rifapentine plus moxifloxacin-based regimen for intensive phase treatment of smear-positive pulmonary tuberculosis. http://clinicaltrials.gov/ct2/show/NCT00728507 (accessed on 9 November 2009).
81. NCT00864383. Controlled comparison of two moxifloxacin containing treatment shortening regimens in pulmonary tuberculosis. http://clinicaltrials.gov/ct2/show/NCT00864383 (accessed on 9 November 2009).
82. NCT01498419. Evaluation of 8 weeks of treatment with the combination of moxifloxacin, PA-824 and pyrazinamide in patients With drug sensitive and multi drug-resistant pulmonary tuberculosis (TB). http://clinicaltrials.gov/ct2/show/NCT01498419 (accessed on 25 May 2012).
83. AIDS Clinical Trials Group. Early bactericidal activity (EBA) study of tuberculosis regimens with and without INH and moxifloxacin [Essentiality of isoniazid after the first two doses: a randomized phase IIa clinical trial comparing the early bactericidal activity (EBA) of a standard anti-tuberculosis regimen (RHZE) with a regimen omitting isoniazid (RZE) or a regimen substituting moxifloxacin for isoniazid (RMZE) during days 3 to 14 of tuberculosis therapy]. http://clinicaltrials.gov/show/NCT01589497 2013.
84. Michael Hoelscher. Evaluation of SQ109, high-dose rifampicin, and moxifloxacin in adults with smear-positive pulmonary TB in a MAMS Design (PanACEA-MAMS-TB-01) [A multiple arm, multiple stage, phase 2, OL, randomized, controlled trial to evaluate 4 treatment regimens of SQ109, increased doses of rifampicin, and Moxifloxacin in Adults with newly diagnosed, smear-positive pulmonary tuberculosis]. http://clinicaltrials.gov/ct2/show/NCT01785186 accessed March 2013.
85. Alangaden GJ, Lerner SA. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clinical Infectious Diseases 1997;25(5):1213-21.
86. Anonymous. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis. Tubercle 1983;64(3):153-66.
87. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al.American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. American Journal of Respiratory Critical Care Medicine 2003;167(4):603-62.
88. Burman WJ, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clinical Infectious Diseases 1999;28(3):419-30.
89. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al.The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Archives of Internal Medicine 2003;163(9):1009-21.
90. Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, Jacobs WR Jr, et al.An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. New England Journal of Medicine 1992;326(4):231-5.
91. El-Sadr WM, Perlman DC, Denning E, Marts JP, Cohn DL. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clinical Infectious Diseases 2001;32(4):623-32.
92. Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, et al.WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. European Respiratory Journal 2011;38(3):516-28.
93. Gillespie SH, Kennedy N. Fluoroquinolones: a new treatment for tuberculosis?. International Journal of Tuberculosis and Lung Disease 1998;2(4):265-71.
94. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infectious Diseases 2003;3(7):432-42.
95. Grzybowski S, Barnett GD, Styblo K. Contacts of cases of active pulmonary tuberculosis. Bulletin of the International Union Against Tuberculosis 1975; Vol. 50, issue 1:90-106.
96. Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
97. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane.org/resources/handbook/hbook.htm.
98. Jacobs MR. Activity of quinolones against mycobacteria. Drugs 1999;58(Suppl 2):19-22.
99. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009;4(9):e6914.
100. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 1991;72(1):1-6.
101. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Search for studies. In: Higgins JPT, Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane.org/resources/handbook/hbook.htm.
102. Reynolds JEF, Parfitt K, Parsons AV, Sweetmann SC, editors. Martindale: the extra pharmacopoeia. 1st Edition. London: Royal Pharmaceutical Society, 1996:1881.
103. The Nordic Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Centre, The Cochrane Collaboration, 2008.
104. Anonymous. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months. Tubercule 1981;62(2):95-102.
105. Telzak EE, Chirgwin KD, Nelson ET, Matts JP, Sepkowitz KA, Benson CA, et al.Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health. International Journal of Tuberculosis and Lung Disease 1999;3(4):337-43.
106. WHO Global Tuberculosis Programme. Treatment of tuberculosis: guidelines for national programmes. [WHO/CDS/TB/2003.313]. 3rd Edition. Geneva: World Health Organization, 2003:1-13.
107. World Health Organization. Stop TB Dept. Guidelines for the programmatic management of drug-resistant tuberculosis. [WHO/HTM/TB/2006.361]. Geneva: World Health Organization, 2006:38-53.
108. World Health Organization. WHO model list of essential medicines: 15th edition. WHO Drug Information 2007;21(2):95-111.
109. World Health Organization. Stop TB Dept. Global tuberculosis control: surveillance, planning, financing: WHO report 2007 [WHO/HTM/TB/2007.376]. http://www.who.int/tb/publications/global_report/2007/download_centre/en/index.html. Geneva: World Health Organization, (accessed August 2007).
110. World Health Organization. Fact File: 10 Facts about tuberculosis. www.who.int/features/factfiles/tb_facts/en/index.html (accessed 8 March 2010).
111. World Health Organisation. Treatment of tuberculosis: guidelines: WHO/HTM/TB/2009.420. 4th Edition. Geneva, Switzerland: World Health Organization, 2009.
112. World Health Organisation. Global tuberculosis control: WHO report 2011. http://www.who.int/tb/publications/global_report/2011/gtbr11_main.pdf 2011:1-73.
113. World Health Organization. WHO Model list of essential medicines: 17th edition. http://whqlibdoc.who.int/hq/2011/a95053_eng.pdf 2011.
114. World Health Organization. Fact sheet No 104: Tuberculosis. http://www.who.int/mediacentre/factsheets/fs104/en/ accessed 25 July 2012.
115. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD000171.pub2]
116. Yew WW. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Safety 2001;25(2):111-33.
117. Ziganshina L, Eisenhut M. Tuberculosis (HIV-negative people). Clinical Evidence 2011;03(904):1-42.
118. Ziganshina LE, Vizel AA, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD004795.pub2]
119. Ziganshina LE, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD004795.pub3]